{{Distinguish|oxandrolone}}
{{Drugbox
| Verifiedfields =
| Watchedfields =
| verifiedrevid =
| IUPAC_name = 16β-Ethylestr-4-en-17β-ol-3-one
| image = Oxendolone.svg
| width =

<!--Clinical data-->
| tradename = Prostetin, Roxenone
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B / C / D / X -->
| pregnancy_category =
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA =
| legal_UK =
| legal_US =
| legal_status =
| routes_of_administration =

<!--Pharmacokinetic data-->
| bioavailability =
| protein_bound =
| metabolism =
| elimination_half-life = 5–6 days ([[intramuscular injection|intramuscular]])<ref name="GaoBohl2005">{{cite journal|last1=Gao|first1=Wenqing|last2=Bohl|first2=Casey E.|last3=Dalton|first3=James T.|title=Chemistry and Structural Biology of Androgen Receptor|journal=Chemical Reviews|volume=105|issue=9|year=2005|pages=3352–3370|issn=0009-2665|doi=10.1021/cr020456u|pmid=16159155|pmc=2096617}}</ref>
| excretion =

<!--Identifiers-->
| CAS_number_Ref =
| CAS_number = 33765-68-3
| CAS_supplemental =
| ATC_prefix =
| ATC_suffix =
| PubChem = 36592
| DrugBank_Ref =
| DrugBank =
| ChemSpiderID_Ref =
| ChemSpiderID = 392001

<!--Chemical data-->
| C=20 | H=30 | O=2
| molecular_weight = 302.451 g/mol
| smiles = CCC1CC2C3CCC4=CC(=O)CCC4C3CCC2(C1O)C
| StdInChI_Ref =
| StdInChI = 1S/C20H30O2/c1-3-12-11-18-17-6-4-13-10-14(21)5-7-15(13)16(17)8-9-20(18,2)19(12)22/h10,12,15-19,22H,3-9,11H2,1-2H3/t12?,15?,16-,17?,18+,19+,20?/m1/s1
| StdInChIKey_Ref =
| StdInChIKey = FCKLFGKATYPJPG-LNRSQMQGSA-N
| synonyms =
}}

'''Oxendolone''' ([[International Nonproprietary Name|INN]], [[United States Adopted Name|USAN]], [[Japanese Accepted Name|JAN]]) (brand names '''Prostetin''', '''Roxenone'''; former developmental code name '''TSAA-291'''), also known as '''16β-ethyl-19-nortestosterone''' or '''16β-ethylestr-4-en-17β-ol-3-one''', is a [[steroid]]al [[antiandrogen]] and [[progestin]] of the [[19-nortestosterone]] group that has been marketed in [[Japan]] by [[Takeda]] for the treatment of [[benign prostatic hyperplasia]] (BPH) since 1981.<ref name="Elks2014">{{cite book|author=J. Elks|title=The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies|url=https://books.google.com/books?id=0vXTBwAAQBAJ&pg=PA914|date=14 November 2014|publisher=Springer|isbn=978-1-4757-2085-3|pages=914–}}</ref><ref name="Publishing2013">{{cite book|author=William Andrew Publishing|title=Pharmaceutical Manufacturing Encyclopedia, 3rd Edition|url=https://books.google.com/books?id=_J2ti4EkYpkC&pg=PA2935-IA129|date=22 October 2013|publisher=Elsevier|isbn=978-0-8155-1856-3|pages=2935–}}</ref><ref name="NegwerScharnow2001">{{cite book|author1=Martin Negwer|author2=Hans-Georg Scharnow|title=Organic-chemical drugs and their synonyms: (an international survey)|url=https://books.google.com/books?id=zmpqAAAAMAAJ|year=2001|publisher=Wiley-VCH|isbn=978-3-527-30247-5|page=2023}}</ref><ref name="TanLi2014">{{cite journal|last1=Tan|first1=MH Eileen|last2=Li|first2=Jun|last3=Xu|first3=H Eric|last4=Melcher|first4=Karsten|last5=Yong|first5=Eu-leong|title=Androgen receptor: structure, role in prostate cancer and drug discovery|journal=Acta Pharmacologica Sinica|volume=36|issue=1|year=2014|pages=3–23|issn=1671-4083|doi=10.1038/aps.2014.18|pmid=24909511}}</ref><ref name="IshizukaNishizawa2002">{{cite journal|last1=Ishizuka|first1=Osamu|last2=Nishizawa|first2=Osamu|last3=Hirao|first3=Yoshihiko|last4=Ohshima|first4=Shinichi|title=Evidence-based meta-analysis of pharmacotherapy for benign prostatic hypertrophy|journal=International Journal of Urology|volume=9|issue=11|year=2002|pages=607–612|issn=0919-8172|doi=10.1046/j.1442-2042.2002.00539.x|pmid=12534901}}</ref> It binds to the [[androgen receptor]] (AR) (K<sub>i</sub> = 320 nM) and [[progesterone receptor]] (K<sub>i</sub> = 20 nM) and acts as a weak but clinically relevant [[enzyme inhibitor|inhibitor]] of [[5α-reductase]] ([[IC50|IC<sub>50</sub>]] = 1.4 μM).<ref>{{cite book|title=Annual Reports in Medicinal Chemistry|url=https://books.google.com/books?id=HrALiG-4t7UC&pg=PA199|date=8 September 1989|publisher=Academic Press|isbn=978-0-08-058368-6|pages=199–}}</ref><ref name="Shinogi1991">{{cite book|title=Annual report of Shionogi Research Laboratories|url=https://books.google.com/books?id=kR40AAAAIAAJ|year=1991|pages=76–77}}</ref><ref name="KirbyChristmas1991">{{cite journal|last1=Kirby|first1=RogerS.|last2=Christmas|first2=Timothy|title=The potential value of 5-alpha-reductase inhibition in the treatment of bladder outflow obstruction due to benign prostatic hyperplasia|journal=World Journal of Urology|volume=9|issue=1|year=1991|issn=0724-4983|doi=10.1007/BF00184713}}</ref><ref name="BashirelahiGanesan1986">{{cite journal|last1=Bashirelahi|first1=N.|last2=Ganesan|first2=S.|last3=Ekiko|first3=D.B.|last4=Young|first4=J.D.|last5=Shida|first5=K.|last6=Yamanaka|first6=H.|last7=Takahashi|first7=E.|title=Effect of 16β-ethyl-17β-hydroxy-4-estren-3-one (tsaa-291) on the binding of promegestone (r5020) and methyltrienolone (r1881) to hyperplastic and neoplastic human prostate|journal=Journal of Steroid Biochemistry|volume=25|issue=3|year=1986|pages=367–374|issn=0022-4731|doi=10.1016/0022-4731(86)90249-9}}</ref> The [[binding affinity]] of oxendolone for the AR is far lower than that of [[cyproterone acetate]].<ref name="GaoBohl2005">{{cite journal|last1=Gao|first1=Wenqing|last2=Bohl|first2=Casey E.|last3=Dalton|first3=James T.|title=Chemistry and Structural Biology of Androgen Receptor|journal=Chemical Reviews|volume=105|issue=9|year=2005|pages=3352–3370|issn=0009-2665|doi=10.1021/cr020456u|pmid=16159155|pmc=2096617}}</ref> At the AR, oxendolone is not a [[silent antagonist]] but is rather predominantly antagonistic with weak [[agonist]]ic activity;<ref name="Shinogi1991" /> for this reason, it has been described as a [[selective androgen receptor modulator]].<ref name="HikichiYamaoka2015">{{cite journal|last1=Hikichi|first1=Yukiko|last2=Yamaoka|first2=Masuo|last3=Kusaka|first3=Masami|last4=Hara|first4=Takahito|title=Selective androgen receptor modulator activity of a steroidal antiandrogen TSAA-291 and its cofactor recruitment profile|journal=European Journal of Pharmacology|volume=765|year=2015|pages=322–331|issn=0014-2999|doi=10.1016/j.ejphar.2015.08.052|pmid=26335395}}</ref> The drug has [[antigonadotropic]] properties via its progestogenic actions.<ref name="SudoYamazaki1979">{{cite journal|last1=Sudo|first1=K.|last2=Yamazaki|first2=I.|last3=Masuoka|first3=M.|last4=Nakayama|first4=R.|title=IV. EFFECTS OF THE ANTI-ANDROGEN TSAA-291 (16 -ETHYL-17 -HYDROXY-4-OESTREN-3-ONE) ON THE SECRETION OF GONADOTROPHINS|journal=European Journal of Endocrinology|volume=92|issue=3 Supplb|year=1979|pages=S53–S66|issn=0804-4643|doi=10.1530/acta.0.092S053}}</ref> Although oxendolone is approved for the treatment of BPH in Japan, concerns have been raised about its use for this condition due to poor efficacy seen in [[clinical trial]]s.<ref name="IshizukaNishizawa2002" />

==See also==
* [[Steroidal antiandrogen]]
* [[List of steroidal antiandrogens]]

==References==
{{Reflist|2}}

{{Drugs used in benign prostatic hypertrophy}}
{{Antiandrogens}}
{{Progestogens}}
{{Androgenics}}
{{Progestogenics}}

[[Category:5α-Reductase inhibitors]]
[[Category:Antiandrogens]]
[[Category:Drugs for benign prostatic hyperplasia]]
[[Category:Estranes]]
[[Category:Progestogens]]


{{steroid-stub}}